LDLilian Downie

Lilian Downie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lilian Downie has a total of 161 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Investigator perspectives on gene selection for public health genomic newborn screening

    by Heidi L. Cope, Rebecca R. Moultrie, Ana N. Forsythe, Holly L. Peay, Lilian Downie, Nina B. Gold, Sula Hood

  • Selection of Genetic Conditions for Multi-State Genomic Newborn Screening in BRIDGES-NBS

    by Nina B. Gold, Britt A. Johnson, Harini Somanchi, Thomas Minten, Stephanie A. Coury, Carrie Blout Zawatsky, Amber Begtrup, Elizabeth Butler, Katherine G. Langley, Rebekah Zimmerman, et al.

  • Open Access

    Global recommendations for the use of diagnostic genomic sequencing in the prenatal setting on behalf of the ESHG and ISPD

    by Zandra C. Deans, Lina Basel Salmon, Kwong Wai Choy, Guido de Wert, Zirui Dong, Lilian Downie, Francesca Romana Grati, Sabine Hentze, Paula Jorge, Brynn Levy, et al.

  • Open Access

    Global Recommendations for the Use of Diagnostic Genomic Sequencing in the Prenatal Setting on Behalf of the ESHG and ISPD

    by Zandra C. Deans, Lina Basel Salmon, Kwong Wai Choy, Guido de Wert, Zirui Dong, Lilian Downie, Francesca Romana Grati, Sabine Hentze, Paula Jorge, Brynn Levy, et al.

  • Open Access

    Scaling up genomic newborn screening: implementation lessons from the BabyScreen+ study

    by Nathasha Kugenthiran, Erin Tutty, Anaita Kanga-Parabia, Jade Caruana, Katrina Scarff, Nitzan Lang, Lilian Downie, Sebastian Lunke, Alison D. Archibald, Zornitza Stark, et al.

    Interest in the potential of population-based genomic sequencing is growing. However, integrating a large-scale screening program into an already complex healthcare system is challenging. The implementation of gNBS needs a thorough understanding of the process. The purpose of this study is to investigate how gNBS can be integrated into the Australian health system and delivered at scale. Embedded within the BabyScreen+ study, we utilised a research design informed by process mapping and phenomenology. Fifty-one semi-structured interviews with parents ( n = 33), healthcare providers ( n = 15), and BabyScreen+ study team members ( n = 8) were conducted. Additionally, we analysed the operational team meeting minutes. A baseline process map, developed in consultation with team members, consisted of six stages: 1. Raising awareness of the screening program; 2. Offer; 3. Participant enrolment and consent; 4. Sample collection; 5. Testing; and 6. Result disclosure and management. We recorded changes made over the study period to inform the post-implementation process map. Most changes occurred at stages: 1. Raising awareness, 4. Sample collection and 5. Testing. Lastly, a process map to inform the scale up of screening, was developed. Four key aspects of the gNBS process needing modification are: (1) growing awareness of screening amongst the public and HCPs; (2) building flexibility and accessibility into the consent process; (3) developing automation capabilities and infrastructure for large-scale sequencing and analysis, and (4) dedicated referral processes for infants who receive high-chance results. These findings demonstrate key system-level considerations and provide a foundation for implementing genomic newborn screening at scale within existing healthcare systems.


  • Open Access

    Australian parents’ perspectives on extended genomic screening: what information to return and when?

    by Fiona Lynch, Christopher Gyngell, Stephanie Best, Clara Gaff, Lilian Downie, Alison Archibald, Ilias Goranitis, Julian Savulescu, Sebastian Lunke, Zornitza Stark, et al.

    Genomic newborn screening (gNBS) has the potential to generate information that remains relevant across the lifespan, yet little is known about how families who have directly experienced gNBS, understand its long-term role and value. This study analysed the results of eight focus groups with 32 parents whose children had received findings from gNBS (through the BabyScreen+ study, a population-based Australian gNBS pilot programme), to explore how they conceptualise the use of genomic information beyond infancy (which we refer to as extended genomic sequencing, or eGS). Parents described a complex interplay of factors including treatability, severity, certainty, and personal capacity to manage information that shaped their desire to receive results. Using the Health Belief Model as a lens, we show how parental reflections mapped to constructs such as perceived benefits, barriers, severity, susceptibility, self-efficacy, and cues to action. However, parents’ reasoning was dynamic rather than static, illustrating how shifts in clinical options or family circumstances influence decision making over time. Overall, our findings demonstrate that families view gNBS data as a potential lifetime resource and support the need for flexible consent pathways, ongoing counselling, and governance frameworks that anticipate both the benefits and burdens of genomic information. This work offers timely insights to inform ethical implementation of eGS in Australia and contributes to international discussions about integrating genomic sequencing into population-level screening.

  • Open Access

    How parents decide whether to have genomic newborn screening: experiences from BabyScreen+

    by Anaita Kanga-Parabia, Erin Tutty, Nathasha Kugenthiran, Jade Caruana, Lilian Downie, Clara Gaff, Nitzan Lang, Sebastian Lunke, Katrina Scarff, Zornitza Stark, et al.

    Education and consent processes for genomic newborn screening (gNBS) must be informed by evidence about parental decision-making. BabyScreen+ piloted gNBS for 1000 newborns in Victoria, Australia. Prospective parents consented online with genetic counselling available on request. We aimed to explore how BabyScreen+ participants ( n = 1139) made decisions about gNBS using a convergent parallel mixed methods design. Demographic ( n = 1080), survey ( n = 1010), and interview ( n = 24) data were analysed using descriptive statistics, logistic regression, and deductive content analysis mapped to the Health Belief Model (domains indicated in italics) . Most participants perceived low susceptibility of having a child with a genetic condition and found it difficult to conceptualise severity . Participants were motivated to consider gNBS due to benefits such as information about their child’s health, reassurance, and research contributions. Some perceived barriers included inequitable access to gNBS information, difficulty navigating high chance results, and potential data misuse. Most participants (987/1139, 87%) proceeded with gNBS because they believed barriers were outweighed by benefits or were manageable due to high self-efficacy . Remaining participants (152/1139, 13%) did not proceed with gNBS because benefits were unclear, or due to low self-efficacy . Experiences were modified by sociodemographic factors and the BabyScreen+ model of care. This research provides timely evidence about parental gNBS decision-making. It supports acceptability and feasibility of the BabyScreen+ model of care. Moving forward, education and consent processes must be equitable, tailored to individual context, and designed to foster self-efficacy. Such considerations will support decision-making and reduce psychological impacts for parents considering gNBS in the future.


  • A de novo WBP11 Pathogenic Variant in a Fetus With Cystic Brain Malformation and Growth Restriction

    by Gulvir Gill, Kelly O'DOnovan, Dina Rubinfeld, Simon Meagher, Stacy Goergen, Lucy Hennington, Alison Fung, Lilian Downie

    We report the first prenatal diagnosis of a de novo WBP11 variant in a fetus with growth restriction and structural brain anomalies. The case highlights the challenges of counselling with a new and evolving gene‐disease association.


  • Open Access

    Insights and Experiences From the ‘Gatekeepers’: A Qualitative Study Exploring Clinician Perspectives on Providing Publicly Funded Prenatal Exome Sequencing

    by Samantha Dayman, Melissa Graetz, Lisa Hui, Lilian Downie

    Background: Genomics has improved etiological diagnosis for foetal structural anomalies. It is being increasingly utilised in prenatal investigation both in Australia and internationally. To date, literature reporting diagnostic yield according to indication has been available. There is limited literature around the challenges of implementation and other aspects of utility. Aims: We aimed to explore the experiences and perspectives of clinicians involved with the delivery of a state‐wide public prenatal exome sequencing (pES) service in Australia. Materials and Methods: This qualitative study was developed using a pragmatism framework. A multidisciplinary cohort of clinicians across all tertiary foetal medicine units in Victoria was interviewed. Inductive content analysis was used to understand the experiences, impact, and utility of pES. Results: Eight clinician interviews were analysed. The impact of pES on clinicians included: increased pressure, higher emotional toll, and balancing the benefits with resource limitations. PES was most useful when it provided prognostic information. The clinicians felt that pES had the most utility for patients when the result informed their decision about whether or not to continue a pregnancy. Clinicians acknowledged their ‘gatekeeper’ role and valued a collaborative, multidisciplinary approach. The main perceived harm for patients was the anxiety associated with waiting times for results. Conclusions: This study provides insights into the delivery of a publicly funded pES program. Our findings highlight the importance of the multidisciplinary team in the successful implementation of genomic technologies in reproductive health.